

Appendix 2: Association between variables in disease risk index and sudden death

Variable	Odds ratio (95% CI)
Age (per 1-year increase)	1.05 (1.03–1.08)
Female sex	0.45 (0.34–0.61)
Income quintile (v. quintile 5)	
1 (lowest)	0.82 (0.56–1.19)
2	0.78 (0.52–1.16)
3	0.66 (0.43–1.01)
4	0.77 (0.47–1.09)
Not in long-term care	0.39 (0.28–0.53)
Prior emergency department visit	1.56 (1.16–2.10)
Prior cardiologist Visit	1.26 (0.87–1.84)
No. of prescription drugs in previous year (continuous)	0.99 (0.97–1.02)
Charlson Comorbidity Index (v. no hospital admission)	
0	0.81 (0.47–1.39)
1	1.06 (0.69–1.63)
2	1.35 (0.91–2.02)
Prior hypertension	0.78 (0.57–1.06)
Prior congestive heart failure	1.29 (0.92–1.82)
Prior diabetes	1.16 (0.82–1.65)
Chronic alcohol use	1.39 (0.39–4.93)
Myocardial infarction	1.00 (0.51–1.94)
Angina	0.65 (0.28–1.50)
Atherosclerosis	2.63 (0.74–9.41)
Cardiomyopathy	1.40 (0.25–7.85)
Chronic kidney disease	0.63 (0.26–1.51)
Other coronary	1.38 (1.01–1.90)
Stroke	1.69 (0.93–3.06)
Angiography	2.35 (1.30–4.27)
Carotid Doppler ultrasonography	0.69 (0.40–1.19)
Carotid endarterectomy	6.55 (0.26–166.3)
Echocardiography	0.88 (0.64–1.23)
Electrocardiography	1.66 (1.19–2.30)
Holter monitor	0.79 (0.51–1.22)
Nuclear medicine stress test	0.64 (0.31–1.29)
Permanent pacemaker insertion	1.24 (0.62–2.49)
Percutaneous transluminal coronary angioplasty	0.62 (0.22–1.74)
Medication use	
ACE inhibitor	1.11 (0.84–1.47)
Angiotensin-receptor blocker	0.85 (0.53–1.47)
Antiarrhythmic drug	1.35 (0.76–2.42)
Anticoagulant	0.88 (0.64–1.20)
Antidepressant	1.01 (0.76–1.33)
ASA or other antiplatelet drug	1.35 (0.80–2.28)
Antipsychotic	1.46 (1.07–2.00)
β -Blocker	0.84 (0.63–1.13)
Calcium-channel blocker	1.03 (0.76–1.40)

continued

Appendix to: Antoniou T, Hollands S, Macdonald EM, et al.; for the Canadian Drug Safety and Effectiveness Research Network. Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone.

CMAJ 2015. DOI:10.1503/cmaj.140816. Copyright © 2015 The Author(s) or their employer(s).
To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca

Cholinesterase inhibitor	0.73 (0.43–1.22)
Digoxin	1.33 (1.00–1.75)
Diuretic	1.40 (0.98–2.01)
Fibrate	2.11 (0.63–7.01)
Insulin	0.96 (0.58–1.58)
Potassium supplement	0.87 (0.44–1.74)
Nitrate	1.31 (0.98–1.74)
NSAID	1.12 (0.76–1.64)
Opiate	1.68 (1.27–2.21)
Oral hypoglycemic agent	1.07 (0.70–1.63)
Prokinetic	1.09 (0.71–1.68)
Sedative hypnotic	1.44 (1.11–1.87)
Statin	0.74 (0.51–1.08)
Infection in preceding 30 days (lower respiratory tract infection, pyelonephritis)	2.95 (1.91–4.57)
Noted: ACE = angiotensin-convertine enzyme, ASA = acetylsalicylic acid, CI = confidence interval, NSAID = nonsteroidal anti-inflammatory drug.	